Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 30'th Apr 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
08:03am, Wednesday, 30'th Apr 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-lice
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
08:03am, Tuesday, 22'nd Apr 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
04:50pm, Thursday, 03'rd Apr 2025
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst tradin
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 28'th Mar 2025
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win
12:21pm, Thursday, 27'th Mar 2025
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Strong Revenue, Drug Performance Lift Catalyst Shares
08:12am, Wednesday, 26'th Mar 2025
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
12:10pm, Tuesday, 25'th Mar 2025
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in t
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
04:05am, Tuesday, 11'th Mar 2025
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
08:03am, Tuesday, 04'th Mar 2025
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
02:39pm, Monday, 03'rd Mar 2025
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 m
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
02:35pm, Thursday, 27'th Feb 2025
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter re
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
12:29pm, Thursday, 27'th Feb 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richa
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
10:10am, Thursday, 27'th Feb 2025
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
